welcomes you to the new, improved website!This randomized trial compared induction therapy for pathologically-proven N2/IIIA NSCLC with 3 cycles of cisplatinum and docetaxel chemotherapy alone to chemotherapy combined with 44 Gy of radiation therapy. 232 pts in 23 centers were enrolled over a 12 year period. No differences were identified in the chemotherapy vs chemoradiotherapy groups for event-free survival (11.6 vs 12.8 mos) or median survival (26.2 vs 37.1).
You are here:
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Submitted by: Mark Ferguson
Source: Lancet
Keywords:
Author(s): Miklos Pless, Roger Stupp, Hans-Beat Ris, Rolf A Stahel, Walter Weder, Sandra Thierstein, Marie-Aline Gerard, Alexandros Xyrafas, Martin Früh, Richard Cathomas, Alfred Zippelius, Arnaud Roth, Milorad Bijelovic, Adrian Ochsenbein, Urs R Meier, Christoph Mamot, Daniel Rauch, Oliver Gautschi, Daniel C Betticher, René-Olivier Mirimanoff, Solange Peters on behalf of the SAKK Lung Cancer Project Group
